A PEGylated version of MGF with extended half-life for sustained satellite cell activation and muscle repair.
PEG-MGF is a PEGylated (polyethylene glycol-conjugated) version of Mechano Growth Factor. The PEGylation process attaches a polyethylene glycol molecule to the peptide, shielding it from enzymatic degradation and dramatically extending its half-life from minutes (native MGF) to several days.
While native MGF acts locally and briefly at the site of muscle damage, PEG-MGF provides sustained systemic exposure. This allows it to circulate and potentially reach multiple sites of muscle damage or stress. The extended half-life also enables less frequent dosing compared to unmodified MGF.
The tradeoff is that the systemic distribution of PEG-MGF may dilute the localized effects that make native MGF effective. Some research protocols use PEG-MGF systemically while applying native MGF locally for site-specific effects.
PEGylation successfully extends MGF half-life while maintaining biological activity. Studies show PEG-MGF promotes satellite cell proliferation and muscle hypertrophy in animal models with more sustained effects than native MGF.
Comparative studies suggest PEG-MGF has different pharmacodynamics than native MGF — the sustained exposure may activate different signaling cascades. The optimal use may involve strategic timing relative to exercise or injury.
📚 Key Reference: PMID: 12855822 (MGF research)
Limited human data. PEG molecules are generally well-tolerated but anti-PEG antibodies can develop with repeated use. Same IGF-1 family safety concerns. Research use only.
NOT FDA-approved. Research use only. WADA prohibited.